The FDA has approved Itvisma for the treatment of children two years and older, teens and adults living with spinal muscular ...

Novartis secured approval for its drug to treat certain patients diagnosed with spinal muscular atrophy from the Food and Drug Administration.

U.S. Food and Drug Administration has approved Novartis' gene therapy for a type of rare muscle disorder, the drugmaker said ...

Basel: Novartis has received approval from the US Food and Drug Administration (FDA) for Itvisma (onasemnogene ...

But while Marley, who was diagnosed at five months, cannot walk or talk and needs help to breathe, Meadow is meeting all the milestones for her age after she was tested at birth and received ...

Muscles are made up of proteins. Myosin, a fibrous protein, serves as a molecular motor and converts the chemical energy stored inside our body into mechanical energy. The synergistic association ...

"The most apparent take-away from the study findings is that a model of developmental therapy focusing on frequency, intensity, and variability of activity, exercise, and self-driven exploration may ...

Novartis today announced that the US Food and Drug Administration (FDA) has approved Itvisma® (onasemnogene abeparvovec-brve) for the treatment of children two years and older, teens, and adults ...

Animals that hibernate are incredibly resilient. They can spend months without food or water, muscles refusing to atrophy, body temperature dropping to near freezing as their metabolism and brain ...